Development Of Oral Natriuretic-like Peptides For Chronic Treatment Of Congestive Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$389,533.00
Summary
Congestive heart failure is fatal disease and a major disease burdon for the community affecting nearly half a million Australians.. Current therapies are inadequate and very limited in prolonging life. We seek to develop a new peptide therepy based on the effectivness of human B type natriuetic peptide which has to be given by injection. Our aim is to produce an orally active and effective treatment based on peptides discovered in snake venom. The program involves testing in animals and cells
Mechanisms Underlying The Contribution Of Uremic Toxins To Cardiorenal Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$413,533.00
Summary
Cardiorenal syndrome (CRS) is an umbrella term that defines disorders of the heart and kidneys whereby “acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other”. We have demonstrated a significant association between heart and kidney fibrosis (scarring) and levels of a uremic toxin called indoxyl sulphate (IS), in relevant animal models and that blockade of production of this toxin reduces cardiac fibrosis. This project aims to explore this association.
Novel Therapy For Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$1,068,984.00
Summary
Heart failure is a major cardiovascular problem. Up to half of the patients have a specific problem with heart muscle relaxation. There is no effective therapy for this type of heart failure. We will investigate the effects of new treatment approach using a range of experimental and clinical methods. If successful the treatment could move quickly into clinical practice.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
I am a cardiovascular clinician-scientist involved in characterising the cellular and molecular pathogenesis of heart failure. My goal is to translate these findings into clinical solutions.
Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
Integrated Basic And Clinical Cardiovascular Research For The Development Of Innovative Approaches To The Treatment Of Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$925,346.00
Summary
Heart failure (HF) is a common cardiovascular problem which causes disabling symptoms and reduces life expectancy. HF is the commonest cause or contributor to hospitalization in people over 65 years. For patients with advanced HF, survival is worse than that for aggresive cancers. At present, for patients with advanced HF and its complications, there are very few treatment options. Over the next 5 years I will conduct a comprehensive series of studies in animal models and in patients to develop ....Heart failure (HF) is a common cardiovascular problem which causes disabling symptoms and reduces life expectancy. HF is the commonest cause or contributor to hospitalization in people over 65 years. For patients with advanced HF, survival is worse than that for aggresive cancers. At present, for patients with advanced HF and its complications, there are very few treatment options. Over the next 5 years I will conduct a comprehensive series of studies in animal models and in patients to develop new treatment options.Read moreRead less
Manipulating Cardiac-selective PI3K Targets To Reverse Heart Failure Progression
Funder
National Health and Medical Research Council
Funding Amount
$532,921.00
Summary
Heart failure is a major clinical problem which is becoming worse as our population ages. New therapeutic strategies with the capability of improving function of the failing heart are greatly needed. We have identified novel targets of a gene with protective properties in the heart. This proposal will examine whether these new targets can reverse heart failure progression. Technologies that target these genes may lead to innovative pharmacotherapies in the clinical management of heart failure.
Mechanically-restricted Percutaneous Gene Therapeutic Solutions For Heart Failure.
Funder
National Health and Medical Research Council
Funding Amount
$187,000.00
Summary
We have developed a novel system for the localized delivery of specialised genes to the heart in order to improve contractility and function of a failing heart. Many genes, for reasons of toxicity, clearance, or uptake, require direct delivery to the target region without spillover to the systemic circulation. Our system addresses these issues by isolating the local circulation of the target organ and directly delivering the agent with minimal systemic loss and improved delivery and uptake effic ....We have developed a novel system for the localized delivery of specialised genes to the heart in order to improve contractility and function of a failing heart. Many genes, for reasons of toxicity, clearance, or uptake, require direct delivery to the target region without spillover to the systemic circulation. Our system addresses these issues by isolating the local circulation of the target organ and directly delivering the agent with minimal systemic loss and improved delivery and uptake efficiency, while minimizing potentially dangerous and toxic systemic effects.Read moreRead less
Mapping In Atrial Fibrillation: A 3-dimensional Electrophysiological Evaluation Of The Electro-pathological Substrate
Funder
National Health and Medical Research Council
Funding Amount
$416,961.00
Summary
Atrial fibrillation is the most frequently encountered heart rhythm disorder. However, mechanisms underlying the progressive nature of this disease remain poorly understood. This study aims to characterize the 3-D electrical dissociation and its relation to pathological changes in conditions predisposing to atrial fibrillation. This knowledge will facilitate the development of individualized, substrate-oriented pharmacological treatment and targeted therapeutic procedures for atrial fibrillation ....Atrial fibrillation is the most frequently encountered heart rhythm disorder. However, mechanisms underlying the progressive nature of this disease remain poorly understood. This study aims to characterize the 3-D electrical dissociation and its relation to pathological changes in conditions predisposing to atrial fibrillation. This knowledge will facilitate the development of individualized, substrate-oriented pharmacological treatment and targeted therapeutic procedures for atrial fibrillation.Read moreRead less